This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

This study has been completed.
Information provided by (Responsible Party):
QRxPharma Inc. Identifier:
First received: November 19, 2009
Last updated: May 15, 2012
Last verified: May 2012
This is a randomized, double-blind, multicenter, fixed dose factorial study of Q8003 12 mg/8 mg versus its individual morphine sulfate and oxycodone hydrochloride components for the management of acute moderate to severe postoperative pain following bunionectomy surgery.

Condition Intervention Phase
Moderate to Severe Postoperative Pain Drug: Q8003 Drug: Morphine sulfate Drug: Oxycodone HCl Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Multi-Center, Repeat-Dose, Comparison of the Analgesic Efficacy and Safety of Q8003 With Oxycodone and Morphine for the Management of Acute Moderate to Severe Postoperative Pain Following Bunionectomy Surgery

Resource links provided by NLM:

Further study details as provided by QRxPharma Inc.:

Primary Outcome Measures:
  • Difference in pain intensity scores from baseline [ Time Frame: 48 hours ]

Secondary Outcome Measures:
  • Safety: adverse events, moderate and severe reports of opioid-related adverse events [ Time Frame: 48 hours ]

Enrollment: 522
Study Start Date: December 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Q8003 12 mg/8 mg
Drug: Q8003
Q8003 is a combination of morphine sulfate and oxycodone HCl
Active Comparator: Morphine sulfate 12 mg
Single component
Drug: Morphine sulfate
One morphine sulfate 12 mg IR capsule q6h
Active Comparator: Oxycodone HCl 8 mg
Single component
Drug: Oxycodone HCl
One oxycodone HCl 8 mg IR Capsule q6h


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is male or female and at least 18 years of age.
  • Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control, or be surgically sterile or postmenopausal (amenorrhea for ≥ 12 months). Non-pregnancy will be confirmed by pregnancy tests conducted at Screening and Pre-treatment.
  • Patient is scheduled for bunionectomy surgery, meets the criteria of an ASA Class I to III, and is willing to stay in the study center for at least 48 hours from the initial dose of study medication post surgery.
  • To be randomized after surgery, the patient must report moderate to severe pain (a score of 2 or more on the 4 point Likert scale or at least 4 on the 11 point NPRS scale).

Exclusion Criteria:

  • In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
  • Used opiates continuously (including tramadol) for more than ten days in the past year.
  • Hypersensitivity or poor tolerance to ibuprofen or short term opioids.
  • Currently receiving any medications that are not at a stable dose (the same dose for > 4 weeks prior to date of surgery).
  • Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003.
  • Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia).
  • Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01016808

United States, California
Investigator Site
Anaheim, California, United States, 92801
United States, Maryland
Investigator Site
Owings Mills, Maryland, United States, 21117
Investigator Site
Pasadena, Maryland, United States, 21122
United States, Texas
Investigator Site
San Antonio, Texas, United States, 78229
United States, Utah
Investigator Site
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
QRxPharma Inc.
Study Director: Patricia T. Richards, MD, Ph.D. QRxPharma Inc.
  More Information

Responsible Party: QRxPharma Inc. Identifier: NCT01016808     History of Changes
Other Study ID Numbers: Q8003-008
Study First Received: November 19, 2009
Last Updated: May 15, 2012

Keywords provided by QRxPharma Inc.:

Additional relevant MeSH terms:
Pain, Postoperative
Neurologic Manifestations
Nervous System Diseases
Postoperative Complications
Pathologic Processes
Signs and Symptoms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on June 23, 2017